Article
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
Journal for immunotherapy of cancer - 1 Aug 2020
Barata Pedro, Agarwal Neeraj, Nussenzveig Roberto, Gerendash Benjamin, Jaeger Ellen, Hatton Whitley, Ledet Elisa, Lewis Brian, Layton Jodi, Babiker Hani, Bryce Alan, Garje Rohan, Stein Cy, Kiedrowski Lesli, Saylor Philip, Sartor Oliver
Abstract excerpt
To report a multi-institutional case series of patients with advanced microsatellite instability high (MSI-H) prostate adenocarcinoma identified with clinical cell-free DNA (cfDNA) next-generation sequencing (NGS) testing and treated with immune checkpoint inhibitors. Retrospective analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) and MSI-H tumor detected by a commercially...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
